Grade My Investments
HomeFree Stock Grades › FRX.TO

Fennec Pharmaceuticals Inc. (FRX.TO) Stock Grade

FRX.TO · Healthcare

C+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$220.6M
P/E Ratio
Revenue Growth (YoY)
-6.1%
Net Margin
-21.8%
Return on Equity
Dividend Yield
None

About Fennec Pharmaceuticals Inc.'s fundamentals

Fennec Pharmaceuticals is a small-cap biotech company with a market capitalization of $220.6 million that reported a net loss in its latest annual statement, resulting in a negative net margin of -21.8%. The company experienced a year-over-year revenue decline of 6.1%, indicating contraction in its top line. As an unprofitable biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not pay dividends.

Track FRX.TO free — no credit card required. Live grade + monthly AI report →